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Murine acute promyelocytic leukemia cells can be
recognized and cleared in vivo by adaptive immune
mechanisms
Alarge number of recent studies haveinvestigated the potential forenhancing the immune response to
detect and eliminate malignant cells in the
host.1,2 Exploiting the molecular specificity
of cellular immune recognition represents
an attractive method for developing tumor-
specific therapies for cancer. The identifica-
tion of T lymphocytes invading and/or sur-
rounding solid tumors in vivo suggested that
T cells recognize cancer cells, although little
evidence exists that these T cells are capa-
ble of killing cells within the tumor. In the
case of leukemia, the evidence for T-cell
detection and elimination has been provid-
ed by clinical responses to donor lympho-
cyte infusions (DLI) in patients following
allogeneic bone marrow transplantation.
DLI can provide curative allogeneic graft-
versus-leukemia (GvL) responses, but they
also cause graft-versus-host disease
(GvHD).3,4 In some leukemia patients, cyto-
toxic T lymphocytes (CTL) specific for the
leukemic clones are capable of killing the
leukemic cells in vitro.5 Despite the potential
for T cells to detect and eliminate leukemia
cells, the majority of AML patients have, by
definition, failed to mount effective
immune responses against their tumors.
The reasons for this failure remain unclear,
but may include inaccessibility of the
tumor cells, evasion of the immune
response by the malignant cells, and/or
inefficient stimulation of the immune sys-
tem by the neoantigens of the tumor cell.6
Acute promyelocytic leukemia (APL) is
primarily associated with the t(15;17)
(q22;q11.2) translocation, which leads to
the expression of novel fusion proteins;
part of the promyelocytic leukemia (PML)
gene is fused in frame with exons 3-9 of the
retinoic acid receptor alpha (RARa) gene.7
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Background and Objectives. In this study, we tested whether transgenic murine acute
promyelocytic leukemia (APL) cells can be recognized and cleared by adaptive immune
responses and/or vaccination strategies.
Design and Methods. Immunocompetent and SCID mice were examined for their abil-
ity to survive a challenge of APL cells. We also vaccinated immunocompetent mice with
DNA vaccines encoding various portions of a bcr-1 PML-RARa fusion protein.
Results. In genetically compatible, immunocompetent animals, APL cells routinely
engrafted and caused lethal leukemia; however, immunodeficient SCID mice required
approximately 100-fold fewer APL cells to cause lethal disease. Massive doses of APL
cells were efficiently eliminated in allogeneic recipients. Vaccination with a plasmid
expressing a human PML-RARa cDNA conferred protection against leukemic cells in
vivo; mice vaccinated with the human PML portion of the fusion gene demonstrated
similar protection. Analysis of 10-mer peptides spanning the t(15;17) translocation-
associated PML-RARa fusion breakpoint suggested that they were not involved in the
generation of immune responses.  
Interpretation and Conclusions. These data show that tumor-specific immune clear-
ance of APL cells does occur in mice.  In this model system, the relevant immunogenic
antigens may arise from the xenogenic PML portion of human PML-RARa, and not
unique sequences derived from the breakpoint region.  However, the study proves that
APL cells are capable of being recognized and killed in vivo by adaptive immune
responses, suggesting that therapeutic vaccines should be possible for this disease
when relevant tumor-specific antigens are identified.
Key words: promyelocytic leukemia, tumor Immunity, DNA vaccines.
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We have previously generated transgenic mice that
express human PML-RARa and RARa-PML (the for-
ward and reciprocal gene products of the transloca-
tion) in early myeloid cells under the control of a
human cathepsin G transgene.8,9 Approximately 60%
of these mice develop APL after a long latent period;
the APL cells from spleens of leukemic mice can be
cryopreserved, and thawed for subsequent in vitro and
in vivo study. These cells can cause fatal APL after
transfer into immunocompetent, genetically compati-
ble secondary hosts.9,10
A recent report has shown that a human PML-RARa
breakpoint-derived DNA vaccine can prevent APL in a
secondary murine transplant model.11 Here, we show
that murine APL cells are capable of being immunolog-
ically recognized, and that the adaptive immune sys-
tem is important for the clearance of murine APL cells
in vivo. We confirm that protective immunity can be
generated by DNA immunization with full-length
PML-RARa, however, equal protection was provided
by the PML portion of the human fusion gene, which
differs significantly from murine PML. Our results also
suggest that the immune response against APL cells
probably does not involve fusion breakpoint sequences.
Thus, while APL cells can be recognized and controlled
by the immune system in vivo, the efficacy of DNA vac-
cination in murine APL models may involve xeno-spe-
cific responses against the human PML portion of the
transgenic fusion protein. Regardless, our data strongly
suggest that effective vaccination approaches should be
possible when appropriate tumor-specific antigens are
identified for this disease.
Design and Methods
Mice
Recipient mice for APL tumor challenge included
male C57Bl/6¥C3H F1 (Taconic, Germantown, NY,
USA), male C3H SCID (Taconic), and female C57Bl/6
(Jackson Labs, Bar Harbor, ME, USA) animals. All mice
were 8-12 weeks of age at the time of tumor challenge.
Cryopreserved APL cells and tumor challenge
The tumor cells used in secondary transfer experi-
ments were derived from cryopreserved splenocytes
from leukemic hCG-PML-RARa¥hCG-RARa-PML
transgenic mice in a C57Bl/6¥C3H F1 (B6C3H) back-
ground.9 Multiple doses of each APL sample were
administered intraperitoneally to B6C3H animals to
determine the minimum dose that reproducibly led to
death from APL in 5/5 recipients (LD100). The LD100 in
immunocompetent animals ranged from 104-106 APL
cells. For allogeneic primary challenge and re-challenge,
cell numbers 3-10 fold above the LD100 were used.
Doses of 106 APL cells were injected for tumor chal-
lenges following DNA immunization. Recipient ani-
mals were monitored for health and physical appear-
ance. Peripheral blood from moribund animals was
sampled via the retro-orbital plexus for blood counts,
and animals with elevated WBC counts (>30,000/mL)
were sacrificed for histopathologic confirmation of dis-
ease in the spleen and liver. Statistical calculations for
all APL cell transfer experiments were performed by
Kaplan-Meier survival analysis, comparing pairs of
curves by the log-rank test, using GraphPad Prism
(GraphPad Software, San Diego, CA, USA). 
Flow cytometry
APL cells and B6C3H F1 splenocytes were stained
with 1 mg of each antibody or the appropriate isotype
control antibody according to the manufacturer’s
instructions. Conjugated antibodies included CD34-
FITC, and PE- conjugated Gr-1, Kk, Kb, I-Ak, and I-Ab (BD
Biosciences Pharmingen, San Diego, CA, USA).
Peptide binding and proliferation assays
Ten 10-mer peptides spanning the bcr-1 PML-RARa
fusion breakpoint, and positive (OVA peptide) and neg-
ative control peptides, were synthesized by standard
methods using an ABI 433A peptide synthesizer
(Biomolecules Midwest Inc., St. Louis, MO, USA).
RMA-S Class I stabilization assays were performed as
described elsewhere.12 3H-thymidine incorporation
assays were performed according to standard proce-
dures using splenocytes from DNA-immunized sur-
vivors of APL cell challenges as responders.13 Stimulator
cells were irradiated wild type B6C3H splenocytes that
were or were not precultured overnight with 100 mM
concentrations of the indicated 10-mer peptides.
DNA immunization
The vector pcDNA3.1 (Invitrogen) was used for all
DNA immunizations. The following cDNA were sub-
cloned into pcDNA3.1: bcr-1 PML-RARa, bcr-3 RARa-
PML, human PML (exons 1-6), human RARa (exons 3-
9), murine GM-CSF, and murine CD40 ligand (CD40L
or CD154). The GM-CSF and CD40L cDNA were gen-
erously provided by Dr. Thomas Kipps. Animals were
vaccinated four times at weekly intervals by intramus-
cular injection in the hind flank with 50 mg of immuniz-
ing plasmid DNA, with or without 50 mg each of the
adjuvant GM-CSF and CD40L plasmid DNA. One
week after the final DNA boost, animals were chal-
lenged with 106 live APL cells intraperitoneally and
monitored for development of APL as described above.
Three independent cryopreserved APL samples were
used in these experiments (10552, 10759, and 10822).
Western blotting
Transient transfection of K562 cells by electropora-
tion and Western blotting of RIPA lysates, harvested
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24 hours after electroporation, was performed as pre-
viously described.14 Antibodies included anti-RARa
(C-20), anti-PML (PG-M3), and anti-actin (C-11) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA).
Results
Murine APL cells express MHC class I and II molecules
T-cell immune responses occur when T lymphocytes
detect differences in MHC class I or II molecules, or
peptides presented within these molecules. Therefore, a
primary requirement for T-cell recognition and elimina-
tion of APL tumor cells is MHC class I and/or class II cell
surface expression. Zheng et al. reported that expression
of PML-RARa in NB4 cells was associated with down-
regulation of MHC class I molecules via inhibition of
TAP transporters and LMP proteins.15 Treatment of NB4
cells with either retinoic acid or interferon resulted in
degradation of PML-RARa, morphologic differentia-
tion, and an increase in expression of TAP and LMP
mRNA. We therefore tested whether transgenic murine
APL cells express MHC molecules. Since our cryopre-
served APL cells are on a mixed C57Bl/6 (H-2b) and C3H
(H-2k) background (B6C3H), we tested for expression of
both H-2b and H-2k haplotypes. 
We previously identified CD34 as an abnormally
expressed surface protein on transgenic APL cells.9 Cell
sorting analysis of CD34+/Gr-1+ cells identified this dis-
tinct, abnormal population of myeloid cells. Two-color
flow cytometric analysis was therefore conducted to
determine whether the CD34-expressing population of
early APL cells expresses MHC cell surface markers. As
shown, all APL samples evaluated express MHC class I
molecules on cells in the CD34+ population (Table 1).
The average individual class I molecule positivity with-
in the CD34+ population was 65%±22% (range of pos-
itivity, 1.0-97.9%). APL cells were also evaluated for
expression of MHC class II molecules. Approximately
15-25% of human AML M3 (APL) samples express
MHC class II molecules.16,17 Using two-color flow
cytometry analysis, 27 of 28 APL samples expressed
MHC class II antigens on >2% of cells within the
CD34+ population (Table 1). The range of positivity var-
ied from 1.0-41.3%, with an average of 14%±11%.
Using separate fluorophores, all MHC class II positive
cells were also positive for MHC class I antigens (data
not shown).
APL cells are efficiently eliminated in allogeneic
recipients, but not in genetically compatible mice
In an allogeneic immune response, foreign cells are
recognized by allo-specific antigenic differences in
MHC class I and II on the cell surface, which trigger a
strong activating response in allogeneic T cells.
Cryopreserved APL cells (H-2b¥H-2k) were injected into
C57Bl/6 animals (H-2b), or into genetically compatible
C57Bl/6¥C3H F1 mice (H-2b¥H-2k), to test the ability of
the recipient allogeneic T cells to detect and eliminate
the donor APL cells. We predicted that the APL cells
would only be rejected if: (i) H-2k antigens are
expressed on the cell surface, and (ii) the APL cells are
susceptible to in vivo recognition and clearance by the
recipient immune system. Five allogeneic C57Bl/6 and
five control B6C3H F1 recipients were injected
intraperitoneally with 3-10 times the LD100 (determined
in genetically compatible B6C3H F1 animals) of three
independent APL tumors (total number of recipient
mice=30). All of the B6C3H mice developed APL and
died within 100 days (Figure 1), which reveals that APL
initiating cells within all samples were capable of
engrafting and expanding in recipient mice if the tumor
cells were not controlled immunologically. In contrast,
all C57Bl/6 animals survived to four months post-chal-
lenge, had normal peripheral blood counts and differen-
tials, and were negative by polymerase chain reaction
monitoring for minimal residual disease in the periph-
eral blood.10 Four months after the initial challenge, the
C57Bl/6 mice were rechallenged with the identical dose
of the same APL tumor sample and again, no animal
developed disease. Animals were sacrificed three
months after the second challenge and were found to
be disease-free by analysis of peripheral blood counts
and by histopathologic evaluation of liver and spleen. 
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Table 1. MHC class I and II surface staining in the CD34+ APL cell
fraction.
APL# MHC class I MHC class II
% Kb %Kk %I-Ab %I-Ak
9638 17.6 36.1 4.8 1.3
10292 10.0 34.7 2.0 1.0
10552 65.4 0 4.0 14.0
10759 34.5 15.0 2.8 1.9
10820 1.0 94.2 4.7 3.9
10822 38.9 84.0 3.2 1.1
10826 0 95.4 7.0 0
10889 0 39.9 4.7 7.1
11030 48.3 0 6.5 0
11193 0 97.9 3.0 4.2
11197 0 40.4 0 1.3
11198 0 29.7 0 2.4
11898 2.5 85.9 28.3 6.1
11899 8.0 97.8 25.2 31.8
11903 48.7 0 24.5 3.6
11904 42.5 0 10.0 0
11908 66.6 0 2.2 1.2
12073 74.1 0 27.6 3.0
13080 0 50.4 41.3 7.9
13081 0 49.8 13.1 2.2
13095 0 92.6 7.8 4.1
13107 1.5 95.3 12.1 6.8
13121 53.4 0 12.3 4.5
14610 0 56.0 2.2 7.3
14617 0 84.0 31.4 7.1
14619 0 72.2 16.7 1.3
14621 0 36.1 3.6 1.7
14866 75.6 0 9.5 0
SCID mice are more susceptible to lethal APL than
and genetically compatible, immunocompetent mice
To determine whether tumor-specific antigen recog-
nition is relevant for clearance, and to define the con-
tribution of the adaptive immune system to protec-
tion, we injected wild type, genetically compatible
immunocompetent mice (B6C3H F1), and C3H SCID
mice (which lack functional T and B cells) with the
same APL tumors. A total of 150 recipient animals
were evaluated in this study (n=5 B6C3H F1 or SCID
mice per group injected with one of three tumor sam-
ples, each transferred at five different doses). At high
tumor cell doses (106 cells), wild type and SCID ani-
mals appeared to be equally susceptible to leukemia
development (Figure 2E and F). However, we
observed a differential susceptibility when smaller
doses of APL cells were injected (Figure 2). The lethal
tumor cell dose for 50% of the recipients (LD50) was
approximately 100-fold lower in SCID recipients than
in wild type B6C3H F1 animals. These data suggest
that the adaptive immune system can clear APL cells
via the recognition of tumor-specific antigens in vivo.
These results also imply that approximately 1 in 200
cells from cryopreserved leukemic spleen samples
contain leukemia-initiating activity (i.e. 100 cells cause
approximately 50% of animals to develop APL).
DNA immunization with human PML-RARa, or the PML
portion of PML-RARa, protects against fatal APL
Injection of naked DNA vectors encoding for
eukaryotic expression of immune antigens has been
shown to elicit robust host responses.18,19 Additionally,
DNA immunization against tumor-specific antigens
can lead to immunologic detection and eradication of
previously tolerated tumors.20,21 Since the PML-RARa
and RARa-PML proteins contain tumor-specific anti-
gens, plasmids were generated to express these cDNA
under the control of the cytomegalovirus promoter in
the pcDNA3.1 expression vector (Invitrogen).
Additionally, to test whether the potential immune
response was directed against the component parts of
the fusion protein, vectors were generated to express
the PML or RARa portions of the bcr-1 derived PML-
Murine APL immunity
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Figure 1. Secondary transfer of APL cells into genetically compat-
ible or allogeneic recipients. The Kaplan-Meier probability of
leukemia-free survival of C57Bl/6¥C3H F1 (B6C3H) or C57Bl/6
(B6) animals is plotted against time after intraperitoneal injection
of the indicated dose of one of three APL tumors (10822, 10759,
and 10292). Open symbols represent B6C3H recipients, and
closed symbols represent B6 recipients (5 mice per group). The
arrow represents the time at which surviving B6 animals were re-
challenged with the same dose of the same APL cells.
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Figure 2.  Dose response to APL cell challenge in immunocompetent or immunodeficient secondary hosts. A-E. The Kaplan-Meier prob-
ability of leukemia-free survival of C57Bl/6¥C3H F1 (B6C3H) or C3H SCID animals is plotted against time after intraperitoneal injection
of APL cells at the following doses: (A) 102 cells per recipient, (B) 103, (C) 104, (D) 105, (E) 106. Triangles indicate B6C3H recipients, and
squares indicate C3H SCID recipients (5 mice per group). F. Percent mortality is plotted as a function of cell dose in B6C3H (filled sym-
bols) or C3H SCID (open symbols) recipients of the three indicated APL tumor samples (total number of recipient mice in this experi-
ment n=150).
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RARa fusion gene (Figure 3A). The expression of the
cloned cDNA in this expression vector was verified by
transient transfection of K562 cells with the indicated
plasmids, followed by Western blotting using antibod-
ies directed against the PML or RARa domains (Figure
3B). The antibodies used do not recognize domains
contained in the reciprocal RARa-PML protein (lane
6), but this vector produced a protein of the expected
size using 35s-methionine-labeled in vitro transcription
and translation (data not shown).
Wild type B6C3H F1 animals were vaccinated by
intramuscular injection of 50 mg of purified plasmid
DNA weekly for four weeks, followed one week later
by challenge with the LD100 dose of intraperitoneally
injected live APL cells (Figure 3C). In some cases, the
immunizations included pcDNA3.1-based constructs
that expressed murine GM-CSF and/or CD40L cDNA;
these adjuvants have been shown to enhance immune
responses in some model systems.22,23 All results were
similar whether or not the adjuvant constructs were
included, and thus all data are combined here. In total,
162 mice were vaccinated four times each with plas-
mid DNA, then injected with live APL cells. Three dif-
ferent APL tumor samples were used to challenge the
immunized mice, with similar results. Animals that
were immunized with the PML-RARa cDNA, or the
PML-portion only, were relatively protected from APL
challenge (Figure 3D, p<0.0001 for PML-RARa or PML
compared pairwise with all other vaccinations by
Kaplan-Meier survival analysis). Vaccination with the
RARa portion of the fusion gene alone, or with a con-
struct expressing 9 amino acids of the PML portion
fused to the entire RARa portion (fus-RARa, see
below), did not result in protection. Similarly, vaccina-
tion with the reciprocal RARa-PML fusion gene did
not confer protection.
PML-RARa breakpoint-derived peptides do not induce
T-cell proliferation in vitro
Despite the observations from DNA immunizations
described above, the amino acids that span the PML-
RARa junction could yield immunogenic peptides not
found in the endogenous PML or RARa proteins; these
peptides could potentially elicit a tumor-specific
J.L. Pollock et al.
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Figure 3. Immunization of secondary tumor recipients with plasmid DNA encoding full-length or partial sequences of PML-RARa. A. The
cDNA constructs used for vaccination are shown. B. Western blotting against PML and RARa is shown for K562 cells transiently trans-
fected with the indicated cDNA. A Western blot that detects b actin is shown as a loading control. Vector represents pcDNA3.1, the vec-
tor backbone in which all cDNA were expressed. C. The schedule for DNA vaccination is shown. Mice were immunized with 50 mg of DNA
four times over four weeks intramuscularly, and were then challenged with a lethal APL tumor dose intraperitoneally. D. The Kaplan-
Meier probability of leukemia-free survival for animals immunized with the indicated cDNA and challenged with 106 murine APL cells is
shown. The number of mice in each group was: vector, n=41; PML-RARa, n=56; PML, n=15; fusion-RARa, n=25; RARa, n=10; RARa-
PML, n=15. The total number of immunized animals was 162. The difference between PML-RARa or PML vaccinated mice vs. any other
immunization is statistically significant (p<0.0001); the difference between PML-RARa and PML vaccinated mice is not statistically sig-
nificant (p=0.08). 
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immune response. We conducted several studies to
address whether the human bcr-1 PML-RARa break-
point region, present in our transgenic tumor cells,
could be a candidate tumor antigen in the murine
immune response against APL. First, ten 10-mer pep-
tides spanning the PML-RARa bcr-1 junction were
tested for their ability to bind and stabilize MHC class
I antigens on the surface of the murine RMA-S cell line.
This cell line expresses H-2b MHC class I molecules,
but is defective in loading of peptides onto MHC mol-
ecules in the endoplasmic reticulum, and thus displays
a very low level of stable surface class I expression.24
When RMA-S cells are incubated with peptides that
bind to H-2b MHC class I molecules, surface expression
is stabilized, and can be observed by fluorescence-
mediated antibody staining. None of the ten break-
point-spanning peptides was able to support MHC
class I expression, whereas a control ovalbumin pep-
tide (OVA) did stabilize expression (Table 2). These
findings show that these ten 10-mers are unlikely to
bind MHC H-2b molecules in intact cells in vivo.
Since binding assays may not be sensitive to all pep-
tides presented in vivo, DNA immunizations were also
conducted with constructs expressing the nine amino
acids in PML upstream of the breakpoint, fused to the
entire RARa sequence. This vector should stimulate
class I immune responses directed against breakpoint
sequences. Vaccination with this construct (Fusion-
RARa) did not result in protection from APL chal-
lenge (Figure 3D). Finally, we tested whether spleno-
cytes from full-length PML-RARa cDNA immunized
animals that survived APL challenge would proliferate
in response to the ten 10-mer breakpoint-derived pep-
tides in a standard one way mixed lymphocyte reac-
tion in vitro. Spleen cells from survivor animals prolif-
erated in response to PMA and ionomycin as predict-
ed, but did not proliferate when co-cultured with
immunologically compatible splenocytes alone, or
splenocytes precultured in the presence of any of the
ten junction peptides (Table 2). Thus, while it remains
possible that a processed peptide of a slightly different
length may bind to MHC class I molecules, it is unlike-
ly that processing of the breakpoint region of PML-
RARa yields peptides that are immunologically recog-
nized in the mouse.
Discussion
In this report, we have shown that transgenic murine
APL cells are capable of being recognized and eliminat-
ed in immunocompetent murine hosts. SCID mice
(which lack T and B cells) were much more susceptible
to APL challenges, suggesting that the adaptive
immune system is important for the clearance of APL
cells in vivo. DNA immunization and peptide studies
suggested that the enhanced immune clearance of
transgenic APL cells in vaccinated animals is probably
not due to recognition of the unique PML-RARa fusion
protein breakpoint region. Rather, recognition of
Murine APL immunity
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Table 2.  PML-RARa breakpoint peptide schematics, MHC class I stabilization, and proliferation assay.
PML ¨] Fusion [Æ RARa RMAS class I 3H-thymidine 
stabilization proliferation
(cpm)
%Db %Kb
1 H V A S G A G E A A 0 0
2 V A S D A G E A A I 0 0
3 A S G A G E A A I E 0 0 1-5 pool 1523
4 S G A G E A A I E T 0 0
5 G A G E A A I E T Q 0 0
6 A G E A A I E T Q S 0 1.6
7 G E A A I E T Q S S 0 0
8 E A A I E T Q S S S 0 0 6-10 pool 3314
9 A A I E T Q S S S S 0 0
10 A I E T Q S S S S E 0 0
DNA V A S G A G E A A I E T Q S S S S E...RARa N/A N/A N/A
Vaccine
(Fusion-RARa)
OVA S I I N F E K L 0 86.0 N/A
Neg S Q T E I A A E G A G S 0 0 2484
Control
No peptide 0 0 5446
PMA+ionomycin N/A N/A 216043
species-specific epitopes of human PML (from the
PML-RARa transgene) may account for the protective
effect of plasmid DNA immunization in mice. These
results indicate that promise exists for utilizing
immune responses against APL cells in vivo, but also
suggests that the optimal antigens for vaccination
and/or immune recognition are still unknown. 
One goal of this work was to determine whether
murine APL cells are capable of being recognized and
killed by the immune system. A previous study report-
ed that PML-RARa may interfere with the normal
function of endogenous PML in regulating the TAP and
LMP components of the endoplasmic reticulum class I
peptide-loading pathway.15 It was suggested that
because of that interference, PML-RARa may cause
downregulation of MHC molecules in APL cells.
However, several studies have questioned this finding
by showing the expected levels of HLA molecules on
human APL cells.17,25,26 Similarly, we have shown here
that most murine APL cells also express MHC class I
and class II. Since murine APL cells are effectively elim-
inated in allogeneic hosts, they likely also express these
surface molecules in vivo, which would make these cells
susceptible to allogeneic recognition and elimination
by the host immune system.
Since the t(15;17) creates a potential tumor-specific
novel antigen, several studies have investigated the
binding and presentation of PML-RARa breakpoint-
derived peptides by HLA molecules. One initial study
found that a human CD4+ T-cell clone could be gener-
ated in vitro that recognized antigen-presenting cells
presenting a PML-RARa junction 25-mer peptide in the
context of HLA-DR.27 However, a subsequent study
found that the same peptide did not stimulate immune
responses in lymphocytes from APL patients in remis-
sion, and no cloned T cells from the same patients
reacted with antigen-presenting cells presenting the
breakpoint peptide.28 When PML-RARa breakpoint
peptides were tested for binding to human HLA class I
molecules, no binding (or only low affinity binding)
was observed, although peptides from other transloca-
tion breakpoints (e.g. the t(9;22) associated BCR-ABL
fusion) bound with high affinity to multiple HLA alle-
les.29,30 Thus, several studies have suggested that pep-
tides in the PML-RARa breakpoint region do not pro-
vide the basis for tumor-specific immune responses
against APL cells.
Nonetheless, alternative antigens presented on APL
cells may exist, since our studies clearly demonstrate a
role for the adaptive immune system in APL cell elimi-
nation in vivo. We previously showed that treatment
with all-trans retinoic acid (ATRA) cooperated with
endogenous T and B cells to eliminate APL cells in vivo.10
Interestingly, a recent report using a different murine
APL model showed the efficacy of a vaccine expressing
a 34 amino acid PML-RARa breakpoint peptide fused
to the tetanus toxin fragment C.11 In vaccinated mice
given transgenic APL cells, protection was only
observed when the mice were concurrently treated
with ATRA. The marker for increased survival in those
mice was the presence of a serum antibody against
RARa, but this antibody was also induced by treat-
ment with ATRA alone, in the absence of any DNA
vaccine. It is not clear whether this antibody is
involved in protective immunity, or whether it serves
only as a marker of anti-leukemic responses. ATRA
treatment of mice bearing transplanted APL cells may
enhance the presentation or processing of alternative
tumor-specific antigens. As such, the cloning of tumor-
specific T cells, or the identification of presented anti-
gens in ATRA-treated mice, may reveal more potent
and efficacious targets for vaccination.
DNA vaccination with a PML-RARa cDNA induces
protective immunity against APL in our mouse model,
and this finding is similar to that reported by Padua et
al.11 In that report, effective vaccination was achieved
using a PML-RARa breakpoint fragment fused to
tetanus toxin fragment C, but full length PML-RARa
did not confer protection. Differences in mouse strains,
schedules and routes of vaccination, and specific APL
cells used, could account for minor differences in the
findings presented here compared with those in
Padua’s report. Most significantly, in contrast to the
experiments presented here, Padua et al. intravenously
transferred APL cells to recipients one week prior to
initiating DNA vaccination. Nonetheless, both reports
convincingly demonstrate that DNA vaccination with
human PML-RARa is protective against transgenic
murine APL tumors. However, in an additional experi-
ment presented here, we found that equally effective
immunity was induced by immunization with only the
PML portion of human PML-RARa. In both studies,
the tumor cells used were obtained from mice trans-
genically engineered to express a human bcr-1 PML-
RARa cDNA in myeloid cells. Human and mouse PML
are only 67% similar at the amino acid level (while
human and mouse RARa are 99% similar), and thus,
the immunogenicity of PML-RARa vaccination in the
mouse may be attributable to xeno-specific differences
within the PML portion of the fusion gene. To illus-
trate, of the 34 amino acids in the PML-RARa fragment
used by Padua et al., 8 of 17 amino acids in the PML
portion of that peptide differ between human and
mouse sequences; all 17 amino acids in the RARa por-
tion are identical in humans and mice. These data sug-
gest that immunization with human PML-RARa  DNA
or peptides in human patients with APL will not be as
effective as that observed in these mouse systems. We
have shown that murine APL cells are not immunolog-
ically cloaked, and that they can be recognized by the
adaptive immune system in both allogeneic and genet-
ically compatible settings. Further, we have shown
J.L. Pollock et al.
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that the anti-APL immune response in the mouse can
be stimulated by DNA vaccination. Recent work with
chronic myeloid leukemia has shown that immune
responses can be stimulated to recognize either fusion
protein-derived antigens (BCR-ABL),31 or a myeloid
specific antigen (proteinase 3)32 that is expressed in
chronic myeloid leukemia cells. However, in light of
the data presented here, and the poor binding of PML-
RARa breakpoint-derived peptides to human HLA
molecules, clinical trials of vaccination in patients with
APL will almost certainly require identification of as
yet unknown APL cell immune antigens. Nonetheless,
these results highlight the potential benefit of sparing
immune function during therapy for leukemia; with or
without vaccination against a tumor-specific antigen,
adaptive immunity may aid the clearance of tumor
cells in vivo.
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